Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants

Patent metadata

Field	Value
Publication number	US-10092644-B2
Application number	US-201415038229-A
Country	US
Kind code	B2
Filing date	Nov 18, 2014
Priority date	Nov 22, 2013
Publication date	Oct 9, 2018
Grant date	Oct 9, 2018

Abstract

Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.

First claim

What is claimed is:

1. A method for enhancing an immune response to an administered vaccine, comprising:
administering a vaccine with an effective amount of an adjuvant comprising a fluorinated cyclic dinucleotide or a pharmaceutically acceptable salt thereof, wherein the fluorinated cyclic dinucleotide has the following structure:

wherein A, C, A′ and C′ are independently selected from NH, O or S; X, Y, X′, and Y′ are independently selected from O or S; Z and Z′ are independently selected from O, S, NH or CH 2 ; and B 1 and B 2 are independently a purine selected from:

wherein Q is hydrogen or NH 2 ; nitrogen is optionally substituted with C 1 -C 6 alkyl or C 1 -C 6 acyl group; and R is O or S.

2. The method according to claim 1 , wherein the fluorinated cyclic dinucleotide is 2′-F-c-di-GMP having the following structure:

3. The method according to claim 1 , wherein said vaccine is an oral vaccine for the prevention or treatment of a H. pylori infection , a C. difficile infection or a Listeria infection.

4. The method according to claim 1 , wherein said vaccine and said adjuvant are administered as separate dosage forms.

5. The method according to claim 1 , wherein said vaccine and said adjuvant are administered as an admixture.

6. The method according to claim 1 , wherein said immune response comprises an antigen-specific mucosal immune response.

7. The method of claim 6 , wherein said immune response is characterized by an antigen-specific secretive IgA antibody response at mucosal sites.

8. The method according to claim 1 , wherein said immune response further comprises an antigen-specific humoral immune response.

9. The method according to claim 1 , wherein said immune response further comprises an antigen-specific cellular immune response.

10. The method according to claim 1 , wherein said vaccine is an oral vaccine or an intranasal vaccine.

Assignees

• Brock Univ
• National Res Council Canada
• Nat Res Council Canada

Inventors

• Yan Hongbin
• Chen Wangxue
• Kuo Lee Rhonda

Classifications

• A61K39/105

  Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title